A majority of lung transplant recipients (LTR) do not respond to the first dose of covid-19 mRNA. Short term antibody responses to the spike protein mRNA are observed after the second dose. In this case series, three patients actually developed “new and significant respiratory compromise after their 2nd vaccine dose.” The respiratory distress was consistent with antibody mediated rejection (AMR). The study authors wrote, “To our knowledge, this is the first published case series of vaccine induced rejection in lung transplant recipients.”
The three fully vaccinated female patients (ages 50-70 years old) were given FDA-approved mRNA vaccines. The three females showed no previous rejection episodes. Two patients received the Moderna variety and one patient received the Pfizer-BioNTech jab. Their serious, life-threatening symptoms began between six month and two years, post-transplant. After the patients were evaluated, antibody mediated rejection was determined to be the underlying etiology of disease. Two of the patients were hospitalized and diagnosed with hypoxic respiratory failure within just two weeks of their second dose of the covid-19 mRNA. One patient exhibited similar symptoms that started out as mild. As time progressed, her symptoms worsened and she required supplemental oxygen and further hospitalization.
The authors report the presence of new donor specific antibodies that “appear to be triggered by the covid-19 vaccine.”MEDICAL SCIENCE WARNING: Lung transplant recipients develop respiratory distress and organ rejection after second dose of covid-19 vaccine – Dr. Eddy Bettermann MD